The stock of Spyre Therapeutics Inc (SYRE) has gone up by 2.11% for the week, with a -5.91% drop in the past month and a -35.26% drop in the past quarter. The volatility ratio for the week is 6.82%, and the volatility levels for the past 30 days are 6.67% for SYRE. The simple moving average for the last 20 days is -0.18% for SYRE stock, with a simple moving average of -23.71% for the last 200 days.
Is It Worth Investing in Spyre Therapeutics Inc (NASDAQ: SYRE) Right Now?
The price-to-earnings ratio for Spyre Therapeutics Inc (NASDAQ: SYRE) is above average at 2.42x. The 36-month beta value for SYRE is also noteworthy at 2.85. There are mixed opinions on the stock, with 10 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for SYRE is 49.95M, and at present, short sellers hold a 20.03% of that float. The average trading volume of SYRE on January 31, 2025 was 586.83K shares.
SYRE) stock’s latest price update
The stock of Spyre Therapeutics Inc (NASDAQ: SYRE) has increased by 1.69 when compared to last closing price of 21.90. Despite this, the company has experienced a 2.11% gain in its stock price over the last five trading sessions. accessnewswire.com reported 2025-01-30 that NEW YORK, NY / ACCESS Newswire / January 30, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (NASDAQ:SYRE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Analysts’ Opinion of SYRE
Many brokerage firms have already submitted their reports for SYRE stocks, with Wedbush repeating the rating for SYRE by listing it as a “Outperform.” The predicted price for SYRE in the upcoming period, according to Wedbush is $45 based on the research report published on September 04, 2024 of the previous year 2024.
Robert W. Baird gave a rating of “Outperform” to SYRE, setting the target price at $50 in the report published on May 02nd of the previous year.
SYRE Trading at -9.13% from the 50-Day Moving Average
After a stumble in the market that brought SYRE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -53.58% of loss for the given period.
Volatility was left at 6.67%, however, over the last 30 days, the volatility rate increased by 6.82%, as shares sank -1.20% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -28.78% lower at present.
During the last 5 trading sessions, SYRE rose by +2.11%, which changed the moving average for the period of 200-days by -40.60% in comparison to the 20-day moving average, which settled at $22.31. In addition, Spyre Therapeutics Inc saw -4.34% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SYRE starting from Albers Jeffrey W., who sale 6,700 shares at the price of $36.76 back on Nov 06 ’24. After this action, Albers Jeffrey W. now owns 27,360 shares of Spyre Therapeutics Inc, valued at $246,313 using the latest closing price.
Albers Jeffrey W., the Director of Spyre Therapeutics Inc, sale 300 shares at $36.43 during a trade that took place back on Oct 25 ’24, which means that Albers Jeffrey W. is holding 34,060 shares at $10,929 based on the most recent closing price.
Stock Fundamentals for SYRE
Current profitability levels for the company are sitting at:
- -185.44 for the present operating margin
- 0.07 for the gross margin
The net margin for Spyre Therapeutics Inc stands at -206.24. The total capital return value is set at -0.53. Equity return is now at value 180.16, with 23.51 for asset returns.
Currently, EBITDA for the company is -127.82 million with net debt to EBITDA at 0.37. When we switch over and look at the enterprise to sales, we see a ratio of 1186.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.32.
Conclusion
In summary, Spyre Therapeutics Inc (SYRE) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
